The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10740 malaria professionals are enjoying the free benefits of MalariaWorld today


Cardiovascular safety and population pharmacokinetic properties of piperaquine in African patients with uncomplicated falciparum malaria - a pooled multicentre analysis

April 23, 2020 - 09:50 -- Open Access
Wattanakul T, Ogutu B, Tarning J, et al.
Antimicrob Agents Chemother. 2020 Apr 20. pii: AAC.01848-19

Dihydroartemisinin-piperaquine has shown excellent efficacy and tolerability in malaria treatment. However, concerns have been raised of potentially harmful cardiotoxic effects associated with piperaquine. The population pharmacokinetics and cardiac effects of piperaquine were evaluated in 1,000 patients, mostly children enrolled in a multicentre trial from 10 sites in Africa.

NOT Open Access | Absence of a High Level of Duplication of the Plasmepsin II Gene in Africa

October 30, 2018 - 12:48 -- NOT Open Access
Marie Gladys Robert, Francis Foguim Tsombeng, Bruno Pradines, et al.
Antimicrob. Agents Chemother. November 2018 62:e00374-18

Resistance to piperaquine has been associated with the amplification of the plasmepsin II gene in Cambodia.


Fitness cost of resistance for lumefantrine and piperaquine-resistant Plasmodium berghei in a mouse model

February 25, 2015 - 15:27 -- Open Access
Winnie R Gimode, Daniel M Kiboi, Francis T Kimani, Hannah N Wamakima, Marion W Burugu, Francis W Muregi
Malaria Journal 2015, 14:38 (28 January 2015)

The study aimed to investigate how resistance against lumefantrine (LU) and piperaquine (PQ), anti-malarials used as partner drugs in artemisinin-based combination therapy (ACT), impacts parasite fitness.

In vitro interaction of lumefantrine and piperaquine by atorvastatin against Plasmodium falciparum

June 9, 2014 - 16:30 -- Open Access
Dormoi J, Savini H, Amalvict R, Baret E, Pradines B
Malaria Journal 2014, 13 :189 (25 May 2014)

Even though in vitro data indicate that atorvastatin improved the activity of lumefantrine and piperaquine, the same may not necessarily be true in vivo.

Medical Treatment: 

MMV in partnership: the Eurartesim(R) experience

June 24, 2013 - 15:30 -- Open Access
Ubben D, Poll EM
Malaria Journal 2013, 12:211 (19 June 2013)

This case study describes how a public-private partnership between Medicines for Malaria Venture (MMV) and Sigma-Tau Industrie Farmaceutiche Riunite SpA achieved international regulatory approval for use of the fixed-dose artemisinin-based combination therapy dihydroartemisinin-piperaquine (Eurartesim(R)) for the treatment of malaria, enabling more widespread access to the medicine in malaria-endemic countries.


Subscribe to RSS - piperaquine